Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2021-04-13 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-04-13 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a confirmation notice from TSX Trust Company regarding the record and meeting dates for the Annual General and Special Meeting of Voyageur Pharmaceuticals Ltd. It specifies dates for the meeting, record dates for notice and voting, and details about the securities entitled to vote. The document does not contain any financial data, management discussion, or detailed report content. It is a formal announcement related to the scheduling and notification of an upcoming shareholder meeting, not the meeting materials or results themselves. Given the short length (1929 characters) and the nature of the content, this fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about meeting logistics rather than a report or detailed filing.
2021-04-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing Health Canada approvals and product licenses for a pharmaceutical product, along with a brief mention that the fiscal 2020 year-end Management Discussion and Analysis and audited financial statements have been filed and uploaded to SEDAR. The main content focuses on product approvals, marketing strategy, and company business plans rather than presenting the actual financial statements or detailed management discussion. The document is relatively short (5622 characters) and serves as an announcement rather than the full annual report or MD&A. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain substantive financial data or detailed report content itself.
2021-04-05 English
52-109F1R - Certification of refiled annual filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification filed by the Chief Financial Officer regarding the refiled annual financial statements for the fiscal year ended November 30, 2020. It is a Form 52-109F1R certificate, which is a regulatory certification of annual filings. The document does not contain the actual financial statements or detailed financial data but rather attests to the accuracy and fair presentation of the annual filings. It also explicitly states it is a certification and not the report itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or other financial reports. The document length is short (3216 characters), and it is a certification, not the full report or announcement of report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2021-04-02 English
52-109F1R - Certification of refiled annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification filed by the CEO regarding the refiled annual financial statements for the fiscal year ended November 30, 2020. It is titled 'FORM 52-109F1R CERTIFICATION OF REFILED ANNUAL FILINGS' and contains attestations about the accuracy and fair presentation of the annual filings. The document is primarily an officer certification and does not contain actual financial statements or substantive financial data. It references the annual filings but does not include them. The document length is 3220 characters, which is relatively short and consistent with a certification letter rather than a full report. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the Annual Report (10-K) or other financial reports.
2021-04-02 English
Audited annual financial statements (amended) - English.pdf
Regulatory Filings
2021-04-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.